门冬氨酸钾镁治疗心力衰竭的临床观察  

Clinical observation of treatment of heart failure by potassium-magnesium aspartate

作　　者：陈丹[1] 薛晶[1] 奚林[2] 党润民[2] 闫宏亮[3] 曹志友[4] 

机构地区：[1]第四军医大学吉林军医学院附属医院心肾内，吉林吉林132013 [2]第四军医大学吉林军医学院附属医院信息科，吉林吉林132013 [3]第四军医大学吉林军医学院附属医院泌尿外科，吉林吉林132013 [4]第四军医大学吉林军医学院附属医院吉林军医学院门诊部，吉林吉林132013

出　　处：《第四军医大学吉林军医学院学报（86813X）》2002年第2期79-80,88,共3页Journal of Jilin Military Medical College Fourth Military Medical University

摘　　要：目的观察门冬氨酸钾镁治疗心力衰竭(HF)的作用。方法随机将128例HF患者分为治疗组(62例)和对照组(66例)，对照组应用常规治疗，治疗组在常规治疗基础上再行门冬氨酸钾镁静滴，观察住院期间两组心律失常的发生率和1年内的死亡率。结果治疗组与对照组恶性心律失常发生率分别为6．5％和19．7％(P＜0．05)，1年内死亡率分别为16．1％和37．9％(P＜0．05)。结论在治疗HF时应用门冬氨酸钾镁可有效降低恶性心率失常的发生率和死亡率。Objective To observe the effects of potassium-magnesium aspartate in treatment of heart failure.Methods 128 cases with HF were randomly divided into the treatment group(62 cases)and the control group(66 cases).In the control group routine treatment was carried out while in the treatment group intravenous injection was added on basis of routine treatment,and then the incidence of arrythmia and death rate within a year were observed in 2 groups during their hospitalization.Results The incidence of mali...

关 键 词：治疗组 门冬氨酸钾镁 对照组 心力衰竭 发生率 死亡率 常规治疗 应用 降低 恶性 

分 类 号：R541[医药卫生—心血管疾病] R554.6[医药卫生—内科学]